Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0165-1875 · 1 trial · 1 indication
Count of adverse events.
| Arm | Type | Description |
|---|---|---|
| NNC0165-1875 | EXPERIMENTAL | Participants will receive NNC0165-1875 alone in cohorts 1-5 (part 1) and NNC0165-1875 along with semaglutide in cohorts 6-11 (part 2). |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo alone in cohorts 1-5 (part 1) and placebo along with semaglutide in cohorts 6-11 (part 2). |
| Name | Type | Description |
|---|---|---|
| NNC0165-1875 | DRUG | Participants will receive a single dose of subcutaneous (s.c.) NNC0165-1875 injection. The planned doses of NNC0165-1875 are as following: cohort 1 and 7: 0.1 mg, cohort 2 and 8: 0.3 mg, cohort 3 and 9: 0.6 mg, cohort 4 and 10: 1.2 mg, cohort 5 and 11: 2.4 mg and cohort 6: 0.03 mg. |
| Placebo (NNC0165-1875) | DRUG | Participants will receive a single dose of s.c. placebo injection. |
| Semaglutide | DRUG | Participants will receive a single dose of s.c. semaglutide 0.25 mg injection. |
Inclusion Criteria: * Males, aged 18-55 years (both inclusive) at the time of signing informed consent * Body mass index (BMI) between 25.0 and 34.9 kg/m\^2 (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator * Body weight greater than or ...
NNC0165-1875 is an investigational small molecule being developed for obesity and overweight. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities. The drug is being studied in people who are overweight or obese, with the goal of addressing these metabolic conditions.
NNC0165-1875 is being developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker NVO. The company is conducting clinical research on this investigational drug for the treatment of obesity and overweight.
NNC0165-1875 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. The Phase 1 trial for this drug has been completed.
NNC0165-1875 has been studied in one clinical trial with the identifier NCT03707990. This Phase 1 trial, titled 'A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese,' was completed in the United States and enrolled 88 male participants.
The specific molecular target of NNC0165-1875 has not been disclosed in available information. As a small molecule, it is being investigated for its potential effects in treating obesity and overweight, but its exact mechanism of action is not publicly detailed.